Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait
Affiliations
Affiliations
- Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 760, 51007 Fintas, Kuwait; Microbiology Unit, Department of Laboratories, Farwania Hospital, Kuwait. Electronic address: alfouzan.w@hsc.edu.kw.
- Microbiology Unit, Department of Laboratories, Farwania Hospital, Kuwait.
- Department of Obstetrics and Gynecology, Farwania Hospital, Kuwait.
- Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 760, 51007 Fintas, Kuwait.
Abstract
Objective: The study was undertaken to determine the prevalence of vulvovaginal candidiasis (VVC) among patients with vaginitis, frequency of different Candida species, and their susceptibility profile.
Patients and methods: Over six months period, high vaginal swabs were cultured on Sabouraud's dextrose agar and isolates were identified by culture on CHROMagar Candida and Vitek2 yeast identification system or/and API 20C (BioMerieux, France). Antifungal susceptibility of the Candida isolates was determined by E-test against amphotericin B, flucytosine, fluconazole, voriconazole, posaconazole and caspofungin.
Results: One thousand seven hundred and fifty-two women with vaginitis were screened for the prevalence of Candida spp. Vaginal swab cultures of 231 (13.2%) women yielded Candida spp. The isolation rates of different species were as follows: Candida albicans (73.9%), Candida glabrata (19.8%), Candida kefir (1.94%), Candida tropicalis (0.96%), Candida parapsilosis (0.96%), Candida krusei (0.96%), Candida guilliermondii (0.96%), and Saccharomyces cerevisiae (0.52%). All strains of C. albicans and non-C. albicans were susceptible to most of the antifungal agents tested.
Conclusion: The high frequency with which C. albicans was recovered and its azole susceptibility support the continued use of azole agents for empirical therapy of uncomplicated VVC. However, a larger controlled study is required to determine the role of non-C. albicans in recurrent VVC.
Keywords: Antifongiques susceptibilité; Antifungal susceptibility; Candida spp.; Vulvovaginitis.
Similar articles
Anh DN, Hung DN, Tien TV, Dinh VN, Son VT, Luong NV, Van NT, Quynh NTN, Van Tuan N, Tuan LQ, Bac ND, Luc NK, Anh LT, Trung DM.BMC Infect Dis. 2021 Jun 3;21(1):523. doi: 10.1186/s12879-021-06192-7.PMID: 34082699 Free PMC article.
Maraki S, Mavromanolaki VE, Stafylaki D, Nioti E, Hamilos G, Kasimati A.Mycoses. 2019 Aug;62(8):692-697. doi: 10.1111/myc.12946. Epub 2019 Jun 12.PMID: 31132175
Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, Deku JG, Kasu ES, Mensah P, Agede CY, Dodoo C, Asiamah EA, Tampuori J, Korbuvi J, Opintan JA.BMC Pregnancy Childbirth. 2020 May 6;20(1):266. doi: 10.1186/s12884-020-02963-3.PMID: 32375724 Free PMC article.
Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC.Dan Med J. 2013 Nov;60(11):B4698.PMID: 24192246 Review.
Esfahani A, Omran AN, Salehi Z, Shams-Ghahfarokhi M, Ghane M, Eybpoosh S, Razzaghi-Abyaneh M.Microb Pathog. 2022 Sep;170:105696. doi: 10.1016/j.micpath.2022.105696. Epub 2022 Jul 31.PMID: 35921954 Review.
Cited by
Kan S, Song N, Pang Q, Mei H, Zheng H, Li D, Cui F, Lv G, An R, Li P, Xiong Z, Fan S, Zhang M, Chen Y, Qiao Q, Liang X, Cui M, Li D, Liao Q, Li X, Liu W.Mycopathologia. 2023 Apr;188(1-2):99-109. doi: 10.1007/s11046-022-00687-w. Epub 2022 Nov 15.PMID: 36378354
Ghasemi R, Lotfali E, Rezaei K, Madinehzad SA, Tafti MF, Aliabadi N, Kouhsari E, Fattahi M.Braz J Microbiol. 2022 Dec;53(4):1761-1779. doi: 10.1007/s42770-022-00813-2. Epub 2022 Oct 28.PMID: 36306113 Review.
The evidence for unavailability of systemic antifungals in Senegal.
Diongue K, Diallo MA, Seck MC, Ndiaye M, Badiane AS, Ndiaye D.Ther Adv Infect Dis. 2021 Aug 9;8:20499361211036594. doi: 10.1177/20499361211036594. eCollection 2021 Jan-Dec.PMID: 34394929 Free PMC article. No abstract available.
Human Fungal Infections in Kuwait-Burden and Diagnostic Gaps.
Alfouzan W, Al-Wathiqi F, Altawalah H, Asadzadeh M, Khan Z, Denning DW.J Fungi (Basel). 2020 Nov 21;6(4):306. doi: 10.3390/jof6040306.PMID: 33233367 Free PMC article.
EFSA Panel on Biological Hazards (BIOHAZ); Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Girones R, Herman L, Koutsoumanis K, Lindqvist R, Nørrung B, Robertson L, Ru G, Sanaa M, Simmons M, Skandamis P, Snary E, Speybroeck N, Ter Kuile B, Threlfall J, Wahlström H, Cocconcelli PS, Klein G, Prieto Maradona M, Querol A, Peixe L, Suarez JE, Sundh I, Vlak JM, Aguilera-Gómez M, Barizzone F, Brozzi R, Correia S, Heng L, Istace F, Lythgo C, Fernández Escámez PS.EFSA J. 2017 Mar 14;15(3):e04664. doi: 10.2903/j.efsa.2017.4664. eCollection 2017 Mar.PMID: 32625421 Free PMC article.